Loading... Please wait...
FirstWord
Market access barriers impacting EU5 severe asthma brands: who wins, who loses?
How are market barriers affecting severe asthma biologic drug prescribing? How do barriers affect the market share of brands and which brands gain or lose? Market access barriers mean US clinicians may be limited in their therapy choices, so what drives their prescribing behaviour and how is this shaping the market share of leading severe asthma biologic brands? The answers to these key questions can be found in this March 2019 analysis of the impact of market access barriers on 4 leading severe asthma biologic brands. Based on a survey of 150 EU5 allergists and pulmonologists, Market Access Impact (EU5): Targeted Therapies in Severe Asthma [Biologics] identifies the winners and losers and provides clear brand-level pointers for management action.
First Name*
Last Name*
Email*
Job Title*
Phone
Company Name
Country Name
Company
Job Function
Clean_Company
World_Region
FW_Sub_Type
ProductName
Brand_Name
Account Owner
Account_Type
Lead_Type
Product_Code
UID


customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved